Coherus Loses Bid To Shift Fees To Amgen In Patent Suit

Law360 (November 30, 2020, 4:11 PM EST) -- A U.S. District Court judge in Delaware on Monday shot down Coherus BioSciences Inc.'s bid to shift legal fees to Amgen Inc. in its failed patent infringement suit against Coherus over a blockbuster anti-infection drug.

U.S. District Judge Leonard P. Stark rejected claims by Coherus that Amgen's loss at the motion to dismiss stage before trial was a rarity in patent litigation that backed up its claim that Amgen and affiliate Amgen Manufacturing Limited pursued a weak case that unfairly burdened financially disadvantaged makers of biosimilar products.

"The court's decision to grant the motion to dismiss was based on its resolution...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!